Online inquiry

IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6881MR)

This product GTTS-WQ6881MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CX3CL1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_002996.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6376
UniProt ID P78423
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6881MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4459MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ15463MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ2917MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ3751MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ14710MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ13659MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ15437MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ2385MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW